SMV
ACRS icon

Sofinnova Management VIII’s Aclaris Therapeutics ACRS Stock Holding History

Sofinnova Management VIII’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$38M Hold
1,539,480
– – 20.72% 3
2017
Q3 		$39.7M Hold
1,539,480
– – 24.23% 2
2017
Q2 		$41.8M Hold
1,539,480
– – 23.4% 1
2017
Q1 		$45.9M Sell
1,539,480
-750,000
-33% -$21.6M 24.21% 1
2016
Q4 		$62.1M Buy
+2,289,480
New +$58.4M 34.97% 1

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Sofinnova Management VIII's ACRS Position: Q4 2017 in Review

Sofinnova Management VIII held its Aclaris Therapeutics (ACRS) position steady in Q4 2017 at 1,539,480 shares worth $38M. The position accounts for 20.72% of the portfolio, ranked #3.

Sofinnova Management VIII first reported a position in ACRS in Q4 2016 and has held it in 5 quarters since. The position peaked at $62.1M in Q4 2016. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

  • Sofinnova Management VIII held 1,539,480 shares of Aclaris Therapeutics worth $38M as of Q4 2017.
  • Sofinnova Management VIII left its Aclaris Therapeutics share count unchanged in Q4 2017.
  • Aclaris Therapeutics made up 20.72% of Sofinnova Management VIII's portfolio in Q4 2017, its #3 holding.
  • Sofinnova Management VIII first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 5 quarters since.
  • Sofinnova Management VIII's Aclaris Therapeutics position peaked at $62.1M in Q4 2016.
  • 102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on Sofinnova Management VIII's 13F filing for Q4 2017, filed 14 Feb 2018.